MedWatch

Top picks in English

Amgen to acquire Nuevolution in million-dollar deal

US drug group Amgen has offered to acquire its Danish partner Nuevolution for USD 167 million - an increase by 169 percent relative to Nuevolution's closing price Tuesday this week. The board recommends that the shareholders accept the offer.

New CEO to launch Azanta's product all over Europe

Danish pharmaceutical company Azanta has appointed a new CEO. His main task is to pave the way to the European market for Azanta's drug, which the company already launched in some countries by use of untraditional methods.

Gubra reached milestone in new record year

For the first time ever, Gubra's gross profit exceeded DKK 100 million in 2018. In addition, the Danish contract research organization expanded the workforce with 50 people. CEO Henrik Blou ascribes the development to the company's combination of contract research services and its own research projects.

The Danish left-wing wants companies to give more back to society

Drug groups that develop medicines based on research from universities and hospitals should give more back to society, say three Danish parties. Minister for Higher Education and Science, Tommy Ahlers, and the Danish Association of the Pharmaceutical Industry (Lif) calls the proposal a surtax for the industry.

Novo and Lundbeck have reduced R&D intensity

While a number of international companies in the past five years have reinvested an increasingly larger part of their revenue in R&D, the opposite trend is evident at two of Denmarks largest pharmaceutical companies. But new strategies may change this fact in the coming years.

Chairman: Ambu CEO Lars Marcher was fired

Jens Bager, Chairman of the board in Ambu, confirms that the company has fired CEO Lars Marcher to bring in more international competences for the global launch of a new range of endoscopes.

Millionaire duo invests in Leo Innovation spin-out

Danish e-health company Klikkit has received DKK 2.5 million (USD 370,000) from two business angels for a large-scale launch of the company's app that helps patients change habits and remember their medicine.

US acquisition to strengthen Lundbeck in the long run

It was not just the opportunity to take over a candidate in phase II that made Lundbeck pay up to DKK 2.7 billion for a US company this week. It was mainly the chance to improve the Danish drug group's opportunity to develop brand-new drugs, says CEO Deborah Dunsire.

Novo CEO dismisses price pressure on growing GLP-1 segment

Although Victoza yielded disappointing results in first quarter, and Novo Nordisk's GLP-1 portfolio is generally under pressure, CEO Lars Fruergaard Jørgensen denies that the segment is subject to increased competition or price pressure. The company has no influence on the underlying reasons, he says.